Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Upadacitinib improved multiple immune-related conditions in one patient.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

Alopecia areata treatments often don't lead to lasting improvement.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Vitamin D analogues can significantly help hair regrowth in Alopecia Areata patients.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.